Quanterix Stock Price, News & Analysis

Quanterix Corporation (NASDAQ:QTRX) has announced that its Chairman and CEO, Kevin Hrusovsky, will present virtually at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 10 at 3:50 PM ET. The public can join the webcast via this link, with replays available for 90 days. Additionally, Hrusovsky will appear on The Bio Report podcast on June 3 at 4:00 PM EDT, accessible on various streaming platforms.

Quanterix Corporation (NASDAQ: QTRX) has appointed Masoud Toloue as President, effective June 9, 2021. Toloue brings extensive experience from PerkinElmer, where he significantly grew their diagnostics sector. The company highlighted advancements in diagnostics, particularly in response to COVID-19 and neurological disorders such as Multiple Sclerosis and Alzheimer’s. Toloue's expertise is expected to drive growth as he oversees the diagnostics business and corporate development. Quanterix aims to enhance precision health through innovative digital biomarker technology.

Quanterix Corporation (NASDAQ: QTRX) reported significant financial growth for Q1 2021, with total revenue increasing to $27.2M, up from $15.7M in Q1 2020, driven by a 86% rise in product revenues to $18.2M. The company achieved a gross margin of 60.1%, compared to 43.3% the previous year. Notably, Quanterix received Emergency Use Authorization for its Simoa® SARS-CoV-2 N Protein Antigen Test. The firm raised approximately $270M in a follow-on offering, strengthening its financial position. The demand for neurodegenerative disease assays, particularly for Alzheimer’s, remains robust.

Quanterix Corporation (NASDAQ: QTRX) will release its financial results for Q1 2021 on May 5, 2021, after market close. A conference call hosted by CEO Kevin Hrusovsky will take place at 4:30 p.m. ET to discuss the results and provide a business update. Interested parties can join by phone or through a live webcast available on Quanterix's website. The company specializes in digitizing biomarker analysis, aiming to enhance precision health through early disease detection and improved treatment methods across various therapeutic areas.

Quanterix Corporation (NASDAQ: QTRX) has appointed Laurie Olson to its Board of Directors, effective April 27, 2021. Olson brings over 30 years of pharmaceutical experience, having previously held key roles at Pfizer, including executive vice president of strategy and commercial operations. Her expertise in corporate strategy and market access aligns with Quanterix’s mission to advance precision health through innovative biomarker analysis. Olson's addition is expected to enhance the company's strategic direction as it seeks to leverage its Simoa technology for earlier disease detection and improved treatment.

Quanterix Corporation (NASDAQ:QTRX) announced a webinar set for April 23, 2021, focusing on advancements in neurological biomarkers such as pTau181 and pTau217. This session will feature prominent experts including CEO Kevin Hrusovsky and Dr. Charlotte Teunissen, discussing the opportunities presented by blood plasma biomarkers in conjunction with Simoa^® technology for Alzheimer's Disease research. The event aims to highlight how these innovations can enhance clinical trials and diagnostics in the fight against Alzheimer's.

Quanterix Corporation (NASDAQ: QTRX) has appointed Shawn Stetson as interim CFO effective May 11, 2021, following Amol Chaubal's departure to Waters Corporation. The company is actively seeking a permanent successor. Kevin Hrusovsky, CEO, expressed confidence in Stetson's capabilities and acknowledged Chaubal's valuable contributions during his tenure. Quanterix focuses on digitizing biomarker analysis, offering innovative solutions aimed at enhancing healthcare delivery and disease detection, applicable in multiple therapeutic areas.

Quanterix Corporation (NASDAQ:QTRX) has reported successful utilization of its Simoa® technology for non-invasive detection of SARS-CoV-2 in various sample types. Published findings in Nature Communications suggest over 90% positive agreement and over 98% negative agreement with traditional PCR tests. The company emphasizes the importance of accurate, accessible testing amidst ongoing COVID-19 challenges. CEO Kevin Hrusovsky highlighted the potential for Simoa technology to enhance patient care and research, addressing issues like false negatives in current testing methods.

Quanterix Corporation (NASDAQ:QTRX) announced its ultra-sensitive Simoa technology was featured in 30 presentations at the AD/PD 2021 conference, showcasing its blood-based neurology biomarker assays. The findings emphasize the potential of these biomarkers, like phosphorylated tau and glial fibrillary acidic protein, as pre-screening tools for Alzheimer's and other neurodegenerative diseases, enabling earlier patient recruitment for clinical trials without costly procedures. CEO Kevin Hrusovsky highlighted the transformative capabilities of these tools, marking significant progress in precision health and potential opportunities for drug developers.